# US 2021/0079385 A1 · Method of acquiring or specifying antibody that recognizes target substance and antibody

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0079385 A1
- Document ID: US20210079385A1
- Status: Published application
- Kind: A1
- Application number: 17/106,808
- Filed: 2020-11-30
- Published: 2021-03-18
- Earliest claimed: 2018-05-30
- Assignees: COGNANO, Inc.
- Applicants: COGNANO, Inc.
- Inventors: Shigehisa HIROSE
- Web page: https://patentgrep.com/patent/US20210079385A1

## CPC

- C40B 50/06: Biochemical methods, e.g. using enzymes or whole viable microorganisms
- C07K 1/22: Affinity chromatography or related techniques based upon selective absorption processes
- C07K 16/005: {constructed by phage libraries}
- C07K 16/32: against translation products of oncogenes
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 15/1072: {Differential gene expression library synthesis, e.g. subtracted libraries, differential screening}
- C12Q 1/6809: Methods for determination or identification of nucleic acids involving differential detection
- C07K 2317/10: characterized by their source of isolation or production
- C07K 2317/22: from camelids, e.g. camel, llama or dromedary
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/33: Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

There is provided with a method of acquiring an antibody that specifically recognizes a target substance. This method includes subtracting an antibody group that recognizes a control substance from an antibody group that recognizes the target substance.

## Claims

### Claim 1

A method of acquiring an antibody that specifically recognizes a target substance, comprising subtracting an antibody group that recognizes a control substance from an antibody group that recognizes the target substance.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the antibody is a VHH antibody.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the subtraction detects a difference in a result of a next-generation sequencer.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the antibody is used for classification of a mammalian cell.

### Claim 5 (depends on 1)

The method according to claim 1, wherein the antibody is used for classification of a class of a living thing.

### Claim 6 (depends on 1)

The method according to claim 1, wherein the antibody is used for classification of a virus.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the antibody is used for classification of a molecule.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the subtracting the antibody group that recognizes the control substance from the antibody group that recognizes the target substance includes comparing amino acid sequences of the antibody group that recognizes the target substance with amino acid sequences of the antibody group that recognizes the control substance.

### Claim 9 (depends on 1)

The method according to claim 1, wherein the antibody that specifically recognizes the target substance is included in the antibody group that recognizes the target substance, and
the number of antibodies, in the antibody group that recognizes the control substance, that specifically recognize the target substance is not more than a predetermined threshold.

### Claim 10 (depends on 1)

The method according to claim 1, wherein the antibody is a peptide.

### Claim 11

A specifying method comprising specifying an antibody that selectively recognizes a target substance in comparison to a control substance by comparing amino acid sequences of an antibody group that recognizes the target substance with amino acid sequences of an antibody group that recognizes the control substance.

### Claim 12 (depends on 11)

The specifying method according to claim 11, wherein the antibody specified in the specifying is included in the antibody group that recognizes the target substance, and
the number of antibodies, specified in the specifying, in the antibody group that recognizes the control substance is not more than a predetermined threshold.

### Claim 13 (depends on 11)

The specifying method according to claim 11, wherein the control substance has a structure in which a target site of the target substance is modified, and
the antibody specified in the specifying selectively recognizes the target site of the target substance in comparison to other sites of the target substance.

### Claim 14 (depends on 11)

The specifying method according to claim 11, wherein the control substance is a complex including the target substance having binding at a target site of the target substance, and
the antibody specified in the step of specifying selectively recognizes the target site of the target substance in comparison to other sites of the target substance.

### Claim 15 (depends on 11)

The specifying method according to claim 11, further comprising:
giving the target substance to an animal that produces the antibody;
determining the amino acid sequences of the antibody group that recognizes the target substance among antibody groups induced in the animal; and
determining the amino acid sequences of the antibody group that recognizes the control substance among the antibody groups induced in the animal.

### Claim 16 (depends on 15)

The specifying method according to claim 15, further comprising determining gene sequences of genes that produce the antibody group induced in the animal,
wherein the determining the amino acid sequences of the antibody group that recognizes the target substance includes:
causing a phage, in which a gene having the determined gene sequence is introduced, to interact with the target substance; and
specifying an amino acid sequence corresponding to the gene sequence introduced into the phage bound to the target substance as the amino acid sequence of the antibody that recognizes the target substance, and
the determining the amino acid sequences of the antibody group that recognizes the control substance includes:
causing a phage, in which a gene having the determined gene sequence is introduced, to interact with the control substance; and
specifying an amino acid sequence corresponding to the gene sequence introduced into the phage bound to the control substance as the amino acid sequence of the antibody that recognizes the control substance.

### Claim 17 (depends on 16)

The specifying method according to claim 16, wherein the determining the gene sequences of the genes that produce the antibody group induced in the animal includes determining a gene sequence of a gene of an antibody, the gene being included in a lymphocyte obtained from the animal.

### Claim 18 (depends on 15)

The specifying method according to claim 15, wherein the antibody is a VHH antibody, and the animal is an alpaca.

### Claim 19 (depends on 11)

The specifying method according to claim 11, further comprising manufacturing the antibody including the specified amino acid sequence.

### Claim 20

An antibody manufactured in accordance with a manufacturing method comprising:
specifying an antibody that selectively recognizes a target substance in comparison to a control substance by comparing amino acid sequences of an antibody group that recognizes the target substance with amino acid sequences of an antibody group that recognizes the control substance; and
manufacturing the antibody including the specified amino acid sequence.
